SYK

Stryker Corporation (STRYKER CORP) - 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2004. Stryker Corporation is a global leader in the orthopaedic market and a major medical device company. Operations are divided into two reportable segments: Orthopaedic Implants (reconstructive, trauma, spine, micro implants) and MedSurg Equipment (powered surgical instruments, endoscopy, imaging, patient handling). The company also provides Physical Therapy Services. All share and per-share data have been adjusted to reflect a two-for-one stock split effective May 14, 2004.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 22% year-over-year, driven by a 14% increase in unit volume/mix, 5% from favorable foreign currency exchange rates, and 3% from price increases.
• Segment Performance: Orthopaedic Implants sales rose 23% to $633.1 million; MedSurg Equipment sales rose 21% to $341.6 million; Physical Therapy Services rose 16% to $60.4 million.
• Profitability: Net earnings increased 31% to $135.9 million. Operating income grew 24%.
• Expense Trends: Selling, general, and administrative (SG&A) expenses increased 22% (39.7% of sales vs. 39.9% prior year), partly due to higher sales commissions and insurance costs. Intangibles amortization increased 42% due to a branding initiative.
• Cash Flow: Operating cash flow decreased 46% to $57.9 million compared to $107.5 million in Q1 2003, primarily due to the timing of income tax payments and higher accounts receivable balances.
• Debt Reduction: Total borrowings declined by $10.2 million during the quarter. Interest expense dropped significantly to $1.4 million from $7.0 million due to lower debt balances and rates.

Guidance, Outlook, and Risks

• 2004 Outlook: Management expects diluted net earnings per share to approximate $1.40 for the full year. Net sales growth is projected at approximately 18%.
• Currency Impact: If exchange rates hold at current levels, the company anticipates a favorable impact on net sales of approximately $30 million in Q2 and $110 million for the full year 2004.
• Capital Allocation: The company plans to invest in business acquisitions, new product instrumentation, and manufacturing facility expansions. It expects cash earnings to exceed working capital needs.
• Risks: Key risks include regulatory actions affecting pricing/demand, changes in third-party reimbursement levels, product liability claims, foreign exchange volatility, and competitive pressures.
• Unusual Items: A $22.4 million loss in accumulated other comprehensive gain was recorded due to the weakening of foreign currencies relative to the U.S. dollar. No cash dividends were declared in Q1 2004 (a dividend of $0.07/share was paid in Jan 2004 for the prior year).

Investor Verification Checklist

• Verify the sustainability of the 22% sales growth rate, specifically the portion attributed to foreign currency fluctuations versus organic volume growth.
• Monitor the trend in accounts receivable days sales outstanding (increased to 62 days), particularly in the MedSurg segment and Pacific region.
• Confirm the impact of the new branding initiative on future intangibles amortization expenses.
• Track the company's ability to meet the full-year 2004 EPS guidance of $1.40 given the Q1 operating cash flow decline.
• Review the status of the two-for-one stock split effective May 14, 2004, and its impact on share count and liquidity.